Structure via PubChem · Public domain (PubChem)
pipradrol
Sign in to savePipradrol, also known by its brand name Meratran, is a mild central nervous system stimulant that acts as a norepinephrine-dopamine reuptake inhibitor. Developed in the United States in the 1940s and patented in 1953, pipradrol was initially marketed as an antidepressant in the mid-1950s. It was subsequently used as an adjunct treatment for various conditions, including obesity, senile dementia, narcolepsy, and schizophrenia.
In the Vinony graph
Vinony's link graph records 1,698 inbound references to pipradrol, and connects out to Anatomical Therapeutic Chemical Classification System, histamine antagonist and 5-methoxy-N,N-diisopropyltryptamine.
Vinony files it under 2-Piperidinyl compounds, Benzhydryl compounds and Beta-Hydroxyamphetamines.
Vinony links it to 12 Wikipedia language editions.
Chemical data
- Formula
- C18H21NO
- Molecular weight
- 267.4 g/mol
- IUPAC name
- diphenyl(piperidin-2-yl)methanol
- SMILES
- C1CCNC(C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O
- InChIKey
- XSWHNYGMWWVAIE-UHFFFAOYSA-N
- XLogP
- 3
- Polar surface area
- 32.3 Ų
- H-bond donors
- 2
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- attention deficit hyperactivity disorder
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Mass
- 267.162
Show 5 more facts
- canonical SMILES
- C1CCNC(C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O
- chemical formula
- C₁₈H₂₁NO
- Commons category
- Pipradrol
- MCN code
- 2933.33.83
- defined daily dose
- 30
Sources (3)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Dosage
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- References
Pipradrol, also known by its brand name Meratran, is a mild central nervous system stimulant that acts as a norepinephrine-dopamine reuptake inhibitor. Developed in the United States in the 1940s and patented in 1953, pipradrol was initially marketed as an antidepressant in the mid-1950s. It was subsequently used as an adjunct treatment for various conditions, including obesity, senile dementia, narcolepsy, and schizophrenia.
Despite its initial promise and relatively mild stimulant effects compared to stronger alternatives, concerns about its abuse potential led to its regulation and withdrawal from widespread use in many countries during the late 1970s. Pipradrol is now classified as a controlled substance in several nations, including the United Kingdom, where it is typically placed in less restrictive drug schedules due to its lower abuse potential compared to other stimulants.
Excerpted from Wikipedia’s “pipradrol” article, available under the CC BY-SA 4.0 licence.